SEC Comment Letter 0000000000-24-006927 to FibroBiologics, Inc. (FBLG)

FibroBiologics, Inc.
Date: June 17, 2024 · CIK: 0001958777 · Accession: 0000000000-24-006927

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

June 17, 2024

Author

Pete O’Heeron

Form

UPLOAD

Company

FibroBiologics, Inc.

Letter

United States securities and exchange commission logo June 17, 2024 Pete O’Heeron Chief Executive Officer FibroBiologics, Inc. 455 E. Medical Center Blvd., Suite 300 Houston, TX 77598 Re:FibroBiologics, Inc. Draft Registration Statement on Form S-1 Submitted June 10, 2024 CIK No. 0001958777 Dear Pete O’Heeron: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brian P. Fenske, Esq.

Show Raw Text

United States securities and exchange commission logo
June 17, 2024
Pete O’Heeron
Chief Executive Officer
FibroBiologics, Inc.
455 E. Medical Center Blvd., Suite 300
Houston, TX 77598
Re:FibroBiologics, Inc.
Draft Registration Statement on Form S-1
Submitted June 10, 2024
CIK No. 0001958777
Dear Pete O’Heeron:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Brian P. Fenske, Esq.

SecProbe.io